αKlotho, functioning as both an anti-fibrotic and anti-tumor agent, ameliorates impairment of renal structure and function in chronic kidney disease by inhibiting the binding of transforming growth factor-β (TGF-β) to its receptors (88). This evidence concerns the gene TGFB1 and chronic kidney disease.